The past decade has seen a marked expansion of the development and application of mechanism-based pharmacokinetic/pharmacodynamic (PK/PD) models for quantitating the time course of drug responses. A general conceptual scheme that depicts the major processes controlling drug effects is depicted in Fig 1. 1 The potential for drug distribution into a biophase as a rate-limiting step controlling some effects was pointed out by Furchgott 2 and Segre, 3 and the application of a linking compartment in pharmacodynamics was popularized by Sheiner et al. 4 The biosensor process represents the mechanism of action of the drug whereby either receptor binding or turnover of endogenous mediators may be altered. The former can be quantitated with an array of equations reflecting reversible binding of agonist or antagonist to receptors, 5 whereas the latter may require use of indirect response models. 6, 7 Some mechanisms involve irreversible inactivation of cells or enzymes such as those used for chemotherapeutic agents 8 or drugs such as aspirin 9 or omeprazole. 10 Bound receptors or endogenous mediators often activate additional biochemical or physiologic steps with such transduction processes leading to the observed response. 11 Further, there may occur diverse counterregulation, depletion, or tolerance mechanisms that can modify the observed response. 12 A highly mechanistic characterization of pharmacologic responses in relation to dose, time, and other factors requires direct measurement of the diverse steps controlling the action of the drug. This may be feasible with invasive animal studies such as our receptor and gene-mediated models for corticosteroids 13 ; however, the modeling of clinical drug responses has severe limitations. Most typically it is desirable and often feasible to capture a capacity constant such as the maximum induced response (E max ), a sensitivity constant such as the equilibrium dissociation constant (K D ) or related biophase concentration (EC 50 ), the Hill coefficient (γ) if necessary, and perhaps a time constant (τ) that may reflect a major rate-limiting step causing a delay in responses separate from the pharmacokinetics of the drug. Either the rate constant for biophase distribution (k eo ) 4 or the constant for loss of the response variable in indirect response models (k out ) 6 is thus the fourth parameter often generally sought where relevant from clinical data. General expectations in quantitating pharmacodynamic data are that the model applied will be as mechanistically relevant as possible, it will capture the major rate-limiting step or steps in control of drug responses, and it will reflect as many doses, routes, or regimens as possible to allow maximal interpretive and predictive capability.
The purpose of this report is to point out the need and feasibility of considering transduction processes and a simplified nonlinear transduction model as the third major class of PK/PD models for characterizing various drug responses with time delays.
TRANSDUCTION MECHANISMS
Advancements in molecular biology have extended the concept of biologic receptors to include not only structural and ligand-binding properties but also the signal transduction systems with which they are associated. On the basis of structure and transduction mechanisms, there are four major classes of receptors as folPharmacodynamic modeling of time-dependent transduction systems lows: cell membrane receptors that act as ion channels (eg, nicotinic receptor for acetylcholine), cell membrane receptors that transmit signals via G-protein (eg, β-adrenergic receptor), cell membrane receptors that possess or are associated with enzyme or transporter activity (eg, insulin), and cytosolic or nuclear receptors (eg, steroids). 14 The pharmacologic effects of many hormones and drugs are often produced via signal transduction processes. Ligand binding and formation of the ligand-receptor complex initiate a cascade of events, which culminate in the observable physiologic response(s). For most transduction pathways, second messengers such as phospholipases (1,4,5-inositol triphosphate, diacylglycerol), and nucleotide cyclases (cyclic adenosine monophosphate [cAMP], cyclic guanosine monophosphate) are induced and serve to regulate cascade processes. 14 For example, ligand activation of the β-adrenergic receptor stimulates adenylyl cyclase, which is mediated by a G-protein (G s ). 15 Subsequent steps involve accumulation of cAMP, stimulation of cAMP-dependent protein kinase, activation of voltage-sensitive calcium channels, and modification of various cellular proteins as a result of their phosphorylation. 16, 17 Cell membrane receptors involving G-proteins have been purported to be involved in the responses to as many as 45% of all current drug targets. 18 Bhalla and Iyengar 19 have described the complexity of various biochemical signaling networks, as well as some computational insights in modeling such systems.
Steroid receptors (including those for glucocorticoids, sex hormones, thyroid hormones, vitamin D, and retinoids) are soluble cytosolic or nuclear proteins that interact with deoxyribonucleic acid (DNA) and regulate the transcription of specific genes. 20 Free corticosteroids diffuse into cells and interact with cytosolic receptors, and activated drug-receptor complex translocates into the nucleus, causing transcriptional modifications. A recent review discusses potential models, including the formation of nuclear homodimers that bind to DNA glucocorticoid-response elements and activate (transactivation) or repress (transrepression) specific genes, thus regulating the expression of secondary messengers, proteins, or enzymes. 21 Signal transduction processes require time and may manifest as delays in measured drug responses when additional steps are required after receptor activation. Evidence of this concept has been shown experimentally for both membrane and cytosolic receptors. For example, the time required for corticosteroid induction of hepatic tyrosine aminotransferase 13 or muscle glutamine synthetase 22 is on the order of 1 to 2 hours with peak enzyme responses occurring at 5 to 6 hours.
In terms of mathematic modeling, the transit compartment model represents the primary technique currently used to describe time-dependent signal transduction in pharmacodynamics. 11 The transit compartment model relies on a series of differential equations to describe the cascade of events between a mediator or activated receptor (M i ) and a final response (R). A relevant differential equation would be:
where τ is a transit time and γ represents a power coefficient (which can serve to amplify or dampen the transduced signal). Our laboratory has applied this approach to model the receptor/gene-mediated effects of corticosteroids, 13 and it was recently used to characterize effects of propranolol on systolic blood pressure in rats. 23 The transit compartment model is flexible and allows for the linkage between PK and PD but may require additional data regarding receptor dynamics and transduction processes. On the basis of an integration of transit compartment methods with the law of mass action and receptor occupancy theory, we propose a new class of basic pharmacodynamic models with a minimal number of parameters for drugs that exhibit delayed responses resulting from time-dependent transduction processes.
PROPOSED TRANSDUCTION MODEL
A scheme depicting our basic PK/PD model for timedependent transduction is shown in Fig 2. This diagram shows free drug (D f ) interacting with available receptors (R) to form a drug-receptor complex (DR). According to the law of mass action and assuming equilibrium conditions and reversible binding, DR concentrations can be defined as follows:
where B max is the total concentration of receptors and K D is the equilibrium dissociation constant. On the basis of the receptor occupancy theory, the biologic effector signal (E * ) is directly proportional to the concentration of DR, E * = ε · DR, where ε is the intrinsic efficacy of the drug. The maximum induced signal (E max ) is assumed to occur when all receptors are occupied, thus E max = ε · B max . Substituting these variables into equation 2 yields the following:
where C is the free drug concentration at the biophase and EC 50 is the K D concentration. Finally, the production and loss of the observable effect are dependent on first-order rate constants, which are equivalent to the reciprocal of the transit times and which are consistent with the transit compartment model. Thus the rate of change of the effect is dE/dt = E * /τ 1 -E/τ 2 . With an initial setting of τ = τ 1 = τ 2 , the simplest operative equation becomes the following:
Baseline values of the PD marker (E 0 ) can be reflected by allowing the measured effect to equal E 0 ± E. It can be shown that when a baseline response is incorporated into equation 4, the equation describing the rate of change of the observable response is mathematically identical to indirect response model I for inhibition and model III for stimulation. 6 Therefore the mathematic properties of only the simplest case will be the same as those of indirect response models I and III (eg, initial slope, area under effect curve, peak effect, and recession slope).
In a preliminary demonstration of this model, simulations were conducted to assess the responses to increasing drug doses (Fig 3) . All simulations were performed with the ADAPT II computer program. 24 The PK profiles of a theoretic drug were defined by a monoexponential function: C = Dose · e -ke · t /V, where Dose represents an intravenous bolus dose, V is volume of distribution, and k e is the first-order elimination rate constant (values are reported in the figure). These concentrations were fixed and used as the driving function in simulations of equation 4 (parameter values per figure). Such profiles show the significant delay between maximum drug concentrations (time zero) and the time of peak effect. It is interesting that the times to peak effect were dose dependent, a differential feature from the effect-compartment model. 3, 4, 6 For medium to high dose levels, drug effects decline in parallel in a nearly linear manner, with inflection points near EC 50 values. These profiles mimic the functioning of indirect response model III for stimulation of a response input rate (k in ), 6, 7 but this would not hold true when there are multiple transduction steps.
APPLICATIONS
The β-adrenergic receptors represent cell membrane receptors that transmit intracellular signals via G-proteins. Thus the delay in clinical responses to β-adrenergic agonists may be a result of transduction processes. The time-dependent transduction model (Fig 2) was applied to mean clinical data reported for the selective β 2 -adrenergic agonist terbutaline. 25 The effect-compartment model was used previously to link the PK/PD properties of terbutaline after subcutaneous injection of 0.75 mg. However, the plasma drug concentrations (time to reach maximum concentration [t max ],~1 hour) should be in intimate contact with cell membrane receptors and should approximate drug biophase concentra- tions. Thus an assumption that the delay in PD response is caused by diffusion of active drug to the biophase seems inappropriate. Instead, the delays in forced expiratory volume in 1 second (FEV 1 ) and airway resistance may be a better reflection of the time required for signal transduction. Plasma terbutaline concentrations were well characterized by a 2-compartment open model with linear first-order input and elimination (Fig  4) . These values were fixed as the driving function, and the time course of FEV 1 and airway resistance were modeled according to equation 4. The maximum-likelihood estimator was used in the ADAPT II computer program 24 to estimate E max , EC 50 , τ, and E 0 . The results of the PK/PD analysis are shown in Fig 4, along with the final estimated parameters. The time-dependent transduction model appears to capture well the time course of terbutaline effects, in a manner consistent with its mechanism of action.
This approach can also accommodate relatively longer delayed responses. The basic model was extended to include additional transit compartments and applied to intravenous PK/PD data (10-mIU infusion over 10 minutes) for interferon alfa-n3 (IFN-αn3) . 26 The interferons (IFN) represent a family of endogenous proteins with potent antiviral, antiproliferative, and immunomodulatory effects. 27, 28 Animal studies suggest that IFN distribute into a volume consistent with total body water and that uptake into specific organs and tissues is negligible. 29 Thus plasma concentrations should reflect IFN concentrations at their cell surface receptors. IFN-α and IFN-β share a common biologic cell surface receptor. Their detailed transduction signaling pathways have recently been described 30 along with reports of delayed biologic responses. 26, 31, 32 Two additional transit compartments were added to the basic model in a manner consistent with transit compartment methods as follows:
where E 1 represents the first transit compartment (equation 4) and the observable effect (2´-5´-oligoadenylate synthetase activity) was modeled as E 0 + E 3 . Plasma concentrations of IFN-αn3 were modeled with a 2-compartment open model with a zero-order infusion input and first-order elimination. The predicted concentrations were then fixed as a driving function for modeling the PD response variable (equations 4-6). The PD model parameters were estimated with the maximum likelihood estimator in ADAPT, and the results of model fitting are shown in Fig 5. The time course of drug concentrations and 2´-5´-oligoadenylate synthetase activity was well described by our integrated time-dependent transduction model. The significant time lag between peak drug concentration (10 minutes) and the maximum effect (18 hours) could be explained by means of nonlinear receptor activation and subsequent signal transduction, consistent with IFN pharmacologic characteristics.
DISCUSSION
A new class of highly useful pharmacodynamic models for drugs exhibiting delayed responses owing to transduction signaling processes is described. Whereas traditional transit compartment analyses generally require extensive and invasive animal models, our method allows for transduction systems modeling of human clinical data. This approach emphasizes a relatively new pharmacodynamic parameter, reflective of the time course of postreceptor events (τ). As appreciation for interindividual pharmacodynamic variability continues to increase, 33 applications of transduction models may be used to assess the role of postreceptor events in determining such variability. Furthermore, covariates may be identified that predict or explain the frequency distribution of τ values.
An important feature of these models is their versatility, because they can be extended to include many additional system complexities. For example, when information regarding specific receptor dynamics is known, alternative functions correlating drug concentrations in the biophase and the effective biosignal may be used. Of importance, the ε factor in the model (Fig  2) may be nonlinear, allowing inclusion of the effector concepts of Black and Leff 34 as follows:
where R 0 is the maximum receptor density and K E is the concentration of drug-receptor complex that elicits half-maximal effect. Likewise, the Hill coefficient may be included in equation 3 as a sigmoidicity parameter. With advancements in molecular biology, more detailed information on receptor-ligand binding properties may become available, and in vitro data (k on , k off , receptor density, and the like) could also be added to the model. Finally, the pharmacologic receptor could undergo desensitization 35 and may exist in various conformational states, 36 and effects may be subject to down-regulation or negative feedback inhibition mechanisms. Our fourth-generation model for the receptor/gene-mediated effects of methylprednisolone, which incorporates detailed receptor dynamics (eg, down-regulation and recycling), exemplifies how these complex phenomena can be integrated into such pharmacodynamic models. 13 Other model adjustments and modifications could also be explored with standard modeling criteria (eg, Akaike criterion, analysis of residuals, visual inspection, and others), providing they are consistent with the pharmacology of the system (ie, mechanism-based modeling). For specific drugs whose plasma concentrations do not reflect biophase concentrations, an effect compartment could be added. 4 Different τ values (τ 1 ≠ τ 2 ) could be incorporated to account for specific ratelimiting cascade steps. As shown here, additional transit compartments can be added to accommodate relatively long time delays between peak drug concentrations and maximum biologic effects (equations 5 and 6). Also, signal amplification and dampening can be achieved through the inclusion of power coefficients (equation 1). 11 Finally, transduction components may be incorporated into an indirect response model. 6 E max · C · ᎏ K To summarize, we introduce an approach that brings time-dependent transduction modeling to the clinical arena in a manner consistent with the mechanisms of action of compounds exhibiting such behavior. A model such as depicted in Fig 2 and equation 4 provides a highly useful starting point to capture a time delay caused by postreceptor events with a minimal number of parameters. The model is easily applied, readily captures typical experimental data, and may yield insightful and relevant prediction of drug effects.
